Is it necessary to routinely measure serum tumor markers, and in particular NSE (Neuron Specific Enolase), for the prognostic evaluation of small celllung cancer patients?;Cancer bronchique primitif a petites cellules: Interet du dosage des marqueurs tumoraux seriques pour l'evaluation pronostique

Presse Medicale

Volumn 28, Issue 28, 1999, Pages 1541-1546

  Watine, J ^a   Charet, J C ^a  

^a HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; LACTATE DEHYDROGENASE; NEURON SPECIFIC ENOLASE; SODIUM; TUMOR MARKER; URIC ACID; ENOLASE; SERUM ALBUMIN;

CANCER PATIENT; CLINICAL LABORATORY; HUMAN; LABORATORY TEST; LUNG SMALL CELL CANCER; PROGNOSIS; REVIEW; SODIUM BLOOD LEVEL; BLOOD; ENZYMOLOGY; LUNG TUMOR; PREDICTION AND FORECASTING; REPRODUCIBILITY; SMALL CELL CARCINOMA;

BICARBONATES; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; PHOSPHOPYRUVATE HYDRATASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SERUM ALBUMIN; SODIUM; TUMOR MARKERS, BIOLOGICAL; URIC ACID;

EID: 0033603931     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Ihde DC, Pass HI, Glatstein EJ. Small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology. Fourth Edition. JB Lippincott Company, Philadelphia, USA, 1993:723-58.
2. Société de Pneumologie de Langue Française. Recommandations concernant l'utilisation des marqueurs tumoraux sériques dans la prise en charge des cancers bronchiques primitifs. Rev Mol Resp 1997 ; 14:355-3539.
3. Fielding LP, Fenoglio-Preiser CM, Freedman LS. The future of prognostic factors in outcome prediction for patients with cancer. Cancer 1992 ; 70:2367-77.
4. Quoix E, Hedelin G, Popin E et al. Can we predict very short term survival in small cell lung cancer? Lung cancer 1993 ; 10:229-38.
5. Johnson PWM, Joel SP, Love S ef al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 1993 ; 67:760-6.
6. Jorgensen LGM, Osterlind K, Genolla J et al. Serum neuron specific enolase (S-NSE) and the prognosis in small-cell lung cancer: a combined multivariable analysis on data from nine centres. Br J Cancer 1996 ; 74:463-7. (erratum : page 2043).
7. Osterlind K, Jorgensen LGM, Hansen HH, Cooper EM. Neuron specific enolase (NSE). A sensitive prognostic factor in small cell lung cancer (SCLC). Lung Cancer 1988 ; 4(Suppl):A46.
8. Pujol JL, Grenier J, Michel FB. Neuron specific enolase (NSE) et Cyfra 21-1 en cancérologie pulmonaire. Immunoanal Biol Spé 1993 ; 8:240-2.
9. Pujol JL, Boher JM, Grenier J, Quantin X, Saffont L, Daurès JP. L'énolase neurone-spécifique (NSE) et la surveillance des cancers bronchiques à petites cellules. Une évaluation de l'information pronostique par le modèle de Markov. Rev Mol Respir 1998 ; 15:519-25.
10. American Thoracic Society and European Respiratory Society. Pretreatment Evaluation of Non-Small-cell Lung Cancer. Am J Respir Crit Care Med 1997 ; 156:320-32.
11. Watine J, Charet JC, Augé MC. A propos de la prescription de marqueurs tumoraux sériques dans un hôpital général. Presse Med 1998 ; 27:862.
12. Watine J, Charet JC. Faut-il suivre les sociétés savantes de pneumologie dans leurs recommandations concernant l'utilisation des marqueurs tumoraux sériques dans l'évaluation pronostique des cancers bronchiques primitifs non à petites cellules? Rev Mol Resp 1999 ; 16:139-49.
13. Kaiser J. Tobacco consultants find letters lucrative. Science 1998 ; 281:895-6.
14. IFCC committee on systematic reviewing in laboratory medicine. Systematic reviewing in laboratory medicine. JIFCC 1997 ; 9:154-5.
15. Marshall E. Medline searches turn up cases of suspected plagiarism. Science 1998 ; 279:473-4.
16. Giovanella L, Piantanida R, Ceriani L et al. Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratn 19 (CYFRA 21-1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis. Int J Biol Markers 1997 ; 12:22-6.
17. Milleron B, Cadranel LJ, Lioté H, François T, Scarna H, Akoun G. Prognostic value of serum neuron-specific enolase in small cell lung cancer. Lung Cancer 1988 ; 4(Suppl):abstract A47.
18. Van der Caast A, Van Putten WLJ, Oosterom R, Cozijnsen M, Hoekstra R, Splinter TAW. Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer. Br J Cancer 1991 ; 64:369-72.
19. Watine J, Charet JC. Do blood cell counts and/or differencial have an independent pretherapeutic prognostic value in primary lung cancer? Hematology and Cell Therapy 1998 ; 40:99-106.
20. Albain KS, Crowley JJ, Hutchins L et al. Predictors of survival following relapse or progression of small cell lung cancer. Cancer 1993 ; 72:1184-91.
21. Albain KS, Crowley JJ, Leblanc M, Livingston RB. Determinants of improved outcome in small cell lung cancer: An analysis of the 2580 patients Southwest Oncology Group data base. J Clin Oncol 1990 ; 8:1563-74.
22. Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxidty in small cell lung cancer: expanded Southwest Oncology Group experience. Chest 1991 ; 99:1425-32.
23. Allan SG, Stewart ME, Love S, Cornbleet MA, Smyth JF, Leonard RCF. Prognosis at presentation of small cell carcinoma of the lung, Eur J Cancer 1990 ; 26:703-5.
24. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognosis factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987 ; 39:146-9.
25. Clamon GH, Feld R, Evans WK et al. The effect of adjuvant central intra venous hyperalimentation on the survival and response to treatment of patients with small cell lung cancer : a randomized trial. Cancer Treat Rep 1985 ; 69:167-77.
26. Cohen MH, Makuch R, Johnston-Early A et al. Laboratory parameters as an alternative to performance status in pronostic stratification of patients with small cell lung cancer. Cancer Treat Rep 1981 ; 65:187-95.
27. Dealing MP, Steinberg SM, Phelps R et al. Outcome of patients with small cell lung cancer: effects of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol 1990 ; 8:1042-9.
28. De Wet M, Falkson G, Rapoport BL. Small cell lung cancer: analysis of factors influencing the response to treatment and survival. Oncology 1994 ; 51:523-34.
29. Fischer JR, Schindel M, Bülzebruck H, Lahm H, Krammer PH, Drings P. Decrease of interleukin-2 secretion is a new independent prognostic factor associated with poor survival in patients with small-cell lung cancer. Annals of Oncology 1997 ; 8:457-61.
30. Graus F, Dalmau J, René R et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997 ; 15:2866-72.
31. Gronowitz JS, Bergström R, Nôu E et al. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 1990 ; 66:722-32.
32. Gross AJ, Steinberg SM, Reilly JG et al. Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Research 1993 ; 53:67-74.
33. Hosker HSR, Jones GM, Corns PA. The nutritional status of patients with small cell lung cancer before and during treatment with chemotherapy. Lung cancer 1991 ; 7(Suppl):49.
34. Joos G, Pinson Ph, Watripont P, Brusselle G, Pauwels R. A retrospective analysis of serum NSE and CFA in small cell lung cancer. Lung cancer 1991 ; 7(Suppl):59.
35. Kawahara M, Fukuoka M, Saijo N et al. Prognostic factors and prognostic staging system for small cell lung cancer. Jpn J Clin Oncol 1997 ; 27:158-65.
36. Kelbel C, Omid S, Westermeier T, Lorenz J. Prognosefaktoren des kleinzelligen Bronchialkarzinoms. Pneumologie 1994 ; 48:475-80.
37. Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: post-treatment characteristics in patients surviving 5 to 18+ years; an analysis of 1,714 consecutive patients. J Clin Oncol 1995 ; 13:1215-20.
38. Maetsu I, Pastor M, Gomez-Codina J et al. Pretreatment prognostic factors for survival in small cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Annals of Oncology 1997 ; 8:547-53.
39. Niederle N, Eberhardt W, Hirche H. Prätherapeutishe prognostische Factoren beim kleinzelligen Bronchialkarzinom. Onkologie 1988 ; 11(Suppl.2):34-40.
40. Ohnoshi T, Hiraki S, Nakata Y et al. Pretreatment serum albumin concentration and lactic dehydrogenase activity as prognostic factors with small cell lung cancer. Acta Med Okayama 1982 ; 36:487-90.
41. Osterlind K, Ciampi A, Dombernowsky P, Hansen M, Hansen OP, Hansen HH. Prognostic factors in small cell lung cancer (SCLC). RECPAM analysis on 1.651 pts treated in Copenhagen during 1973-1987. Lung Cancer 1991 ; 7(Suppl):58.
42. Quoix E, Hedelin G, Seibert R et al. Facteurs pronostiques pré-thérapeutiques de la survie dans le cancer bronchique à petites cellules. Etude rétrospective d'une série de 112 patients. Rev Mol Resp 1993 ; 10:29-35.
43. Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990 ; 61:597-604.
44. Rosenfeld MR, Malats N, Schramm L et al. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Nat Cancel Institute 1997 ; 89:381-5.
45. Sagman U, Leblanc M, Maki E, Feld R and the consensus group for prognostic factors in SCLC. Verification of a multicenter prognostic model for small-cell lung carcinoma. Proc Am Soc Clin Oncol 1993 ; 12:337 (abstract 1125).
46. Sagman U, Maki E, Evans WK et al. Small-Cell Carcinoma of the Lung : Derivation of a Pronostic Staging System. J Clin Oncol 1991 ; 9:1639-49.
47. Sagman U, Maki E, Ledesma E, Feld R and the consensus group for prognostic factors in SCLC. A multicentre consensus model for prognostic factors in small cell lung cancer (SCLC). Lung Cancer 1991 ; 7(Suppl):58.
48. Sheehan RC, Balaban EP, Cox JV, Frenkel EP. The relative value of conventional staging procedures for developing prognostic models in extensive-stage small cell lung cancer. J Clin Oncol 1990 ; 8:2047-53.
49. Sheehan RG, Balaban EP, Frenkel EP. The impact of dose intensity of standard chemotherapy regimens in extensive stage small cell lung cancer. Am J Clin Oncol 1993 ; 16:250-5.
50. Shikaura S, Kawa S, Yoshida M, Yonezu S. Results of chemo-radiotherapy and prognostic factors of small cell lung cancer. Radiation Medicine 1991 ; 9:70-6.
51. Souhami RL, Bradbury I, Geddes DM, Spiro SG, Harper PG, Tobias JS. Prognostic significance of laboratory parameters measured at diagnosis in small-cell carcinoma of the lung. Cancer Research 1985 ; 45:2878-82.
52. Stokkel MPM, Van Eck-Smit BLF, Zwinderman AH, Willems LNA, Pauwels EKJ. Pretreatment serum lactate as additional staging parameter in patients with small-cell lung carcinoma. J Cancer Res Clin Oncol 1998 ; 124:215-9.
53. Tamura M, Ueoka H, Kiura K et al. Prognostic factors of small-cell lung cancer in Okayama lung cancer study group trials. Acta Med Okayama 1998 ; 52:105-11.
54. Vincent MD, Ashley SE, Smith IE. Pronostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. Eut J Cancer Clin Oncol 1987, 23:1589-99.
55. Wang T, Feld R, Sagman U et al. The combined use of LDH and CEA as independent prognostic markers for small cell lung cancer. Proc Am Assoc Cancer Res 1986 ; 27:162 (abstract 641).
56. Wojtukiewicz MZ, Zacharski LR, Moritz TE, Hur K, Edwards RL, Rickles FR. Prognostic significance of blood coagulation tests in carcinoma of lung and colon. Blood Coag Fibrin 1992 ; 3:429-37.
57. Work E, Bentzen SM, Nielsen OS, Fode K, Michalski W, Palshof T and The Aarhus Lung Cancer Group. Prophylactic cranial irradiation in limited stage small cell lung cancer : survival benefit in patient with favourable characteristics. Eur J Cancer 1996 ; 32A:772-8.
58. Charet JC, Watine J, Lepretre A, Raimbault C, Charet P. Orosomucoïd: Prealbumin Ratio in the monitoring of lung cancer. Clinical Biochemistry 1996 ; 29:287-90.
59. Studnicka M, Wirnsberger R, Neumann M, Pokieser L, Angeler J. Peripheral blood lymphocyte subsets and survival in small cell lung cancer. Chest 1994 ; 105:1673-8.
60. Perez EA, Loprinzi CL, Sloan JA, Owens DT, Novotny PJ, Bonner JA. Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma. Cancer 1997 ; 80:676-80.
61. Durand-Zalesky I, Rymer JC, Roudot-Thoraval F, Revuz J, Rosa J. Reducing unnecessary laboratory use with new test request form: example of tumour markers. Lancet 1993 ; 342:150-3.
62. Annales du contrôle national de qualité. Biochimie 1995/3. Agence du médicament, ministère des affaires sociales de la santé et de la ville, république française. 1997 No7 (mars):91-160.
63. IFCC Scientific Division Working Group on Selective Electrodes. Use of ion-selective electrodes for blood-electrolyte analysis. Recommendations for nomenclature, definitions and conventions. J Intern Federation Clin Chem 1997 ; 9:16-22.
64. Collège national de biochimie des Hôpitaux et Société française de biologie clinique. L'assurance de la qualité de la phase pré-analytique : le prélèvement. Ann Biol Clin 1997 ; 55:467-508.
65. Buccheri G, Ferrigno D, Vola F, Rosso A, Curcio A. Comparative value of CEA, TPA, and neuron enolase (NE) in small cell lung cancer (SCLC) management. Lung Cancer 1988 ; 4(Suppl):A46.